Vertex Pharmaceuticals Incorporated VRTX

526.19 3.81 0.73% as of 25 Sep
Market cap
$132.3B
P/E
30.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Vertex Pharmaceuticals Incorporated (VRTX) EV/Sales

As of 25 September 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a EV/Sales of 10.0×. Over the past ten years it has ranged from 5.5× (October 2021) to 53.8× (August 2015); the current reading is higher than 41% of that period. That is below the Biotechnology industry median of 10.7× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 9.1× 2.68%
FY2024 8.9× (7.80%)
FY2023 9.6× 36.67%
FY2022 7.1× 7.59%
FY2021 6.6× (26.48%)
FY2020 8.9× (29.95%)
FY2019 12.7× (2.66%)
FY2018 13.1× (11.68%)
FY2017 14.8× 42.69%
FY2016 10.4× (64.36%)

Quarterly

Period EV/Sales Change
Jun 2026 9.4× 7.97%
Mar 2026 8.7× (4.55%)
Dec 2025 9.1× 13.79%
Sep 2025 8.0× (15.29%)
42 more quarters

Against its own ten years

Low 5.5× High 53.8×
Ten-year median 11.3×
Current reading's percentile 41

EV/Sales against peers

Company EV/Sales
REGN Regeneron Pharmaceuticals, Inc. compare 4.9×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 6.0×
ALNY Alnylam Pharmaceuticals, Inc. compare 6.6×
VRTX Vertex Pharmaceuticals Incorporated 10.0×
ARGX argenex SE compare 10.5×
RPRX Royalty Pharma PLC compare 13.4×
INSM Insmed, Inc. compare 22.2×
MRNA Moderna, Inc. compare 33.5×
RVMD Revolution Medicines, Inc. compare 1,499×
Biotechnology industry median 10.7×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on VRTX